189 related articles for article (PubMed ID: 27020088)
41. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
[TBL] [Abstract][Full Text] [Related]
42. Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation.
Ostvik AE; Granlund AV; Bugge M; Nilsen NJ; Torp SH; Waldum HL; Damås JK; Espevik T; Sandvik AK
Inflamm Bowel Dis; 2013 Feb; 19(2):265-74. PubMed ID: 22685032
[TBL] [Abstract][Full Text] [Related]
43. CXCR3/CXCL10 Axis Regulates Neutrophil-NK Cell Cross-Talk Determining the Severity of Experimental Osteoarthritis.
Benigni G; Dimitrova P; Antonangeli F; Sanseviero E; Milanova V; Blom A; van Lent P; Morrone S; Santoni A; Bernardini G
J Immunol; 2017 Mar; 198(5):2115-2124. PubMed ID: 28108560
[TBL] [Abstract][Full Text] [Related]
44. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
45. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Grkovic L; Baird K; Steinberg SM; Williams KM; Pulanic D; Cowen EW; Mitchell SA; Hakim FT; Martires KJ; Avila DN; Taylor TN; Salit RB; Rowley SD; Zhang D; Fowler DH; Bishop MR; Gress RE; Pavletic SZ
Leukemia; 2012 Apr; 26(4):633-43. PubMed ID: 22005783
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
[TBL] [Abstract][Full Text] [Related]
47. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.
Du J; Flynn R; Paz K; Ren HG; Ogata Y; Zhang Q; Gafken PR; Storer BE; Roy NH; Burkhardt JK; Mathews W; Tolar J; Lee SJ; Blazar BR; Paczesny S
Blood; 2018 Apr; 131(15):1743-1754. PubMed ID: 29348127
[TBL] [Abstract][Full Text] [Related]
48. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.
Cuvelier GD; Kariminia A; Fujii H; Aslanian S; Wall D; Goldman F; Grupp SA; Dunn SE; Krailo M; Shapiro LH; Gilman A; Schultz KR
Bone Marrow Transplant; 2010 Nov; 45(11):1653-7. PubMed ID: 20190833
[TBL] [Abstract][Full Text] [Related]
50. Increased proportion of HLA-class-I-specific natural killer cell receptors (CD94) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation.
Tanaka J; Tutumi Y; Zhang L; Mori A; Kahata K; Toyoshima N; Ohta S; Kobayashi S; Hashino S; Asaka M; Imamura M
Acta Haematol; 2001; 105(2):89-91. PubMed ID: 11408710
[TBL] [Abstract][Full Text] [Related]
51. Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis.
Piotrowski WJ; Młynarski W; Fendler W; Wyka K; Marczak J; Górski P; Antczak A
Pol Arch Med Wewn; 2014; 124(7-8):395-402. PubMed ID: 24859629
[TBL] [Abstract][Full Text] [Related]
52. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
[TBL] [Abstract][Full Text] [Related]
53. Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.
Vasconcellos de Souza C; Vigorito AC; Miranda ECM; Garcia C; Rensi Colturato VA; Mauad MA; Rodrigues Moreira MC; da Silva Bouzas LF; Lermontov S; Hamerschlak N; Rodrigues M; Carlos de Almeida Barros J; Chiattone R; Lee SJ; Flowers MED
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1313-1318. PubMed ID: 27058616
[TBL] [Abstract][Full Text] [Related]
54. Sequential analysis of HLA-C-specific killer cell inhibitory receptor (CD158b) expressing peripheral blood mononuclear cells during chronic graft-versus-host disease.
Tanaka J; Tutumi Y; Mori A; Ohta S; Kobayashi S; Asaka M; Imamura M
Bone Marrow Transplant; 2000 Aug; 26(3):287-90. PubMed ID: 10967567
[TBL] [Abstract][Full Text] [Related]
55. CXCL10 stabilizes T cell-brain endothelial cell adhesion leading to the induction of cerebral malaria.
Sorensen EW; Lian J; Ozga AJ; Miyabe Y; Ji SW; Bromley SK; Mempel TR; Luster AD
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669942
[TBL] [Abstract][Full Text] [Related]
56. Identification and validation of biomarkers associated with acute and chronic graft versus host disease.
Ahmed SS; Wang XN; Norden J; Pearce K; El-Gezawy E; Atarod S; Hromadnikova I; Collin M; Holler E; Dickinson AM
Bone Marrow Transplant; 2015 Dec; 50(12):1563-71. PubMed ID: 26367225
[TBL] [Abstract][Full Text] [Related]
57. The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.
Ren HG; Adom D; Paczesny S
Expert Rev Clin Immunol; 2018 May; 14(5):389-404. PubMed ID: 29629613
[TBL] [Abstract][Full Text] [Related]
58. Plasmacytoid dendritic cell heterogeneity is defined by CXCL10 expression following TLR7 stimulation.
Marsman C; Lafouresse F; Liao Y; Baldwin TM; Mielke LA; Hu Y; Mack M; Hertzog PJ; de Graaf CA; Shi W; Groom JR
Immunol Cell Biol; 2018 Nov; 96(10):1083-1094. PubMed ID: 29870118
[TBL] [Abstract][Full Text] [Related]
59. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
[TBL] [Abstract][Full Text] [Related]
60. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.
Pidala J; Sigdel TK; Wang A; Hsieh S; Inamoto Y; Martin PJ; Flowers ME; Hansen JA; Lee SJ; Sarwal MM
J Pathol Clin Res; 2017 Jan; 3(1):3-16. PubMed ID: 28138397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
